Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

New therapeutic frontiers for metabotropic glutamate receptors.

Niswender CM, Jones CK, Conn PJ.

Curr Top Med Chem. 2005;5(9):847-57. Review.

PMID:
16178730
2.

Physiological roles and therapeutic potential of metabotropic glutamate receptors.

Conn PJ.

Ann N Y Acad Sci. 2003 Nov;1003:12-21. Review.

PMID:
14684432
3.

Metabotropic glutamate receptor 7: at the interface of cognition and emotion.

O'Connor RM, Finger BC, Flor PJ, Cryan JF.

Eur J Pharmacol. 2010 Aug 10;639(1-3):123-31. doi: 10.1016/j.ejphar.2010.02.059. Epub 2010 Apr 2. Review.

PMID:
20371242
4.

Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Kew JN, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Epub 2005 Feb 25. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.

PMID:
15731895
5.
6.

Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications.

Slassi A, Isaac M, Edwards L, Minidis A, Wensbo D, Mattsson J, Nilsson K, Raboisson P, McLeod D, Stormann TM, Hammerland LG, Johnson E.

Curr Top Med Chem. 2005;5(9):897-911. Review.

PMID:
16178734
7.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280
8.

Metabotropic glutamate receptors as drug targets.

Récasens M, Guiramand J, Aimar R, Abdulkarim A, Barbanel G.

Curr Drug Targets. 2007 May;8(5):651-81. Review.

PMID:
17504108
9.

Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.

Lesage A, Steckler T.

Eur J Pharmacol. 2010 Aug 10;639(1-3):2-16. doi: 10.1016/j.ejphar.2009.12.043. Epub 2010 Apr 2. Review.

PMID:
20371230
10.

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

Schoepp DD, Jane DE, Monn JA.

Neuropharmacology. 1999 Oct;38(10):1431-76. Review.

PMID:
10530808
11.

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.

Ritzén A, Mathiesen JM, Thomsen C.

Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):202-13. Review.

12.
13.

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.

Moghaddam B.

Psychopharmacology (Berl). 2004 Jun;174(1):39-44. Epub 2004 Feb 19. Review.

PMID:
15205877
14.

mGlu5 receptor antagonists: a novel class of anxiolytics?

Spooren W, Gasparini F.

Drug News Perspect. 2004 May;17(4):251-7. Review.

PMID:
15334174
15.

Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.

Chaki S.

Eur J Pharmacol. 2010 Aug 10;639(1-3):59-66. doi: 10.1016/j.ejphar.2009.12.041. Epub 2010 Apr 2. Review.

PMID:
20371240
16.

Glutamate metabotropic receptors as targets for drug therapy in epilepsy.

Moldrich RX, Chapman AG, De Sarro G, Meldrum BS.

Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16. Review.

PMID:
12969743
17.

Group I metabotropic glutamate receptors: implications for brain diseases.

Bordi F, Ugolini A.

Prog Neurobiol. 1999 Sep;59(1):55-79. Review.

PMID:
10416961
18.

Allosteric modulation of metabotropic glutamate receptors.

Sheffler DJ, Gregory KJ, Rook JM, Conn PJ.

Adv Pharmacol. 2011;62:37-77. doi: 10.1016/B978-0-12-385952-5.00010-5. Review.

19.

Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues.

Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF.

Pharmacol Rev. 2011 Mar;63(1):35-58. doi: 10.1124/pr.110.004036. Epub 2011 Jan 12. Review.

20.

Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders.

Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R.

Behav Pharmacol. 2003 Jul;14(4):257-77. Review.

PMID:
12838033
Items per page

Supplemental Content

Write to the Help Desk